FKBP4 Polyclonal Antibody (E-AB-19050)
For research use only.
| Verified Samples |
Verified Samples in WB: 231, HepG2 Verified Samples in IHC: Human cervical cancer |
| Dilution | WB 1:1000-1:5000, IHC 1:50-1:300 |
| Isotype | IgG |
| Host | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB, IHC |
| Clonality | Polyclonal |
| Immunogen | Fusion protein of human FKBP4 |
| Abbre | FKBP4 |
| Synonyms | 51 kDa FK506-binding protein, 52 kDa FK506 binding protein, 52 kDa FK506-binding protein, 52 kDa FKBP, 59 kDa immunophilin, FK506 binding protein 4, FK506-binding protein 4, FKBP 4, FKBP 52, FKBP 59, FKBP-4, FKBP-52, FKBP4, FKBP51, FKBP52 protein, FKBP59, HBI, Hsp 5 |
| Swissprot | |
| Calculated MW | 52 kDa |
| Observed MW |
Refer to figures
The actual band is not consistent with the expectation.
Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates. The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. The common factors include: 1. Post-translational modifications: For example, modifications such as glycosylation, phosphorylation, methylation, and acetylation will increase the molecular weight of the protein. 2. Splicing variants: Different expression patterns of various mRNA splicing bodies may produce proteins of different sizes. 3. Post-translational cleavage: Many proteins are first synthesized into precursor proteins and then cleaved to form active forms, such as COL1A1. 4. Relative charge: the composition of amino acids (the proportion of charged amino acids and uncharged amino acids). 5. Formation of multimers: For example, in protein dimer, strong interactions between proteins can cause the bands to be larger. However, the use of reducing conditions can usually avoid the formation of multimers. If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane. |
| Cellular Localization | Cytoplasm>cytosol. Nucleus. Cytoplasm>cytoskeleton. |
| Concentration | 1.14 mg/mL |
| Buffer | Phosphate buffered solution, pH 7.4, containing 0.05% stabilizer and 50% glycerol. |
| Purification Method | Antigen affinity purification |
| Research Areas | Cancer, Epigenetics and Nuclear Signaling, Signal Transduction |
| Conjugation | Unconjugated |
| Storage | Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. |
| Shipping | The product is shipped with ice pack,upon receipt,store it immediately at the temperature recommended. |
| background | FKBP52 (FK506 binding protein 4) is a member of the immunophilin protein family that comprises intracellular protein effectors of immunosuppressive drugs,and it is known as a steroid receptor-associated protein. As a novel regulator of microtubule dynamics,FKBP52 is associated with the motor protein dynein and with the cytoskeleton during mitosis. FKBP52 is highly expressed in CNS regions susceptible to Alzheimer's,and plays a role in modulating toxicity of Abeta peptides. The protein can associate with the Tau function,and may help to decipher and modulate the events involved in Tau-induced neurodegeneration. In addition,FKBP52 is likely to play a role in growth and development of the male genitalia. |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
Unconjugated
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
